Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor a... by Enriqueta Felip, Francois Ghiringhelli, Alona Zer, Byoung Chul Cho, Sun Min Lim, Laurent Greillier, Alastair Greystoke, Nuria Pardo, Yaacov R Lawrence, Nedal Al-Sakaff, Hans-Joachim Helms, Hen Prizant, Jan Pintoffl, Farah Louise Lim

Get full text

Real-world treatment patterns and outcomes for patients with non-metastatic non-small cell lung cancer: retrospective analyses in Canada, England, and Germany by Alastair Greystoke, Melinda J. Daumont, Caroline Rault, Hannah Baltus, Philip Q. Ding, Gabrielle Emanuel, Stefano Lucherini, Lien Vo, Valeria M. Saglimbene, Eleanor Ralphs, Cátia Leal, Minouk J. Schoemaker, Alexander Katalinic, Annika Waldmann, Winson Y. Cheung

Get full text

An assessment of circulating biomarkers and germline genetic variants in predicting chemotherapy associated mucositis in Ewing sarcoma by Pawan Gulati, Vickyanne Carruthers, Claire Hutton, Chloe Cassidy, Edward B. Amankwatia, Séréna Pascual, Electra Florence, Tsegay G. Gebru, Andrea L. Jorgensen, Alastair Greystoke, Guy Makin, Martin G. McCabe, Daniel B. Hawcutt, Gareth J. Veal, David Jamieson

Get full text

A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer by Gary Middleton, Helen L. Robbins, Peter Fletcher, Joshua Savage, Manita Mehmi, Yvonne Summers, Alastair Greystoke, Nicola Steele, Sanjay Popat, Pooja Jain, James Spicer, Judith Cave, Paul Shaw, David Gilligan, Danielle Power, Dean Fennell, Maya Bajracharya, David J. McBride, Uma Maheswari, Alexander M. Frankell, Charles Swanton, Andrew D. Beggs, Lucinda Billingham

Get full text